Why the study?
The CiPA initiative proposes that balanced multi-ion channel-blocking drugs have low torsade risk and would not cause heart rate corrected J-Tpeak prolongation.
Does the absence of J-T peak c prolongation identify balanced multi-ion channel-blocking drugs in a Phase I study?
Does the absence of J-T peak c prolongation identify balanced multi-ion channel-blocking drugs in a Phase I study?
Answers are grounded in this paper and cite their sources.
The absence of J-T peak c prolongation appears consistent with balanced multi-ion channel block, supporting its potential utility as an ECG biomarker for proarrhythmia risk assessment.
Balanced multi‐ion channel‐blocking drugs have low torsade risk because they block inward currents. The Comprehensive In Vitro Proarrhythmia Assay (Ci PA ) initiative proposes to use an in silico cardiomyocyte model to determine the presence of balanced block, and absence of heart rate corrected J‐T peak (J‐T peak c) prolongation would be expected for balanced blockers. This study included three balanced blockers in a 10‐subject‐per‐drug parallel design; lopinavir/ritonavir and verapamil met the primary end point of ΔΔJ‐T peak c upper bound < 10 ms, whereas ranolazine did not (upper bounds of 8.8, 6.1, and 12.0 ms, respectively). Chloroquine, a predominant blocker of the potassium channel encoded by the ether‐à‐go‐go related gene (hERG), prolonged ΔΔ QT c and ΔΔJ‐T peak c by ≥ 10 ms. In a separate crossover design, diltiazem (calcium block) did not shorten dofetilide‐induced Δ QT c prolongation, but shortened ΔJ‐T peak c and prolonged ΔT peak ‐T end . Absence of J‐T peak c prolongation seems consistent with balanced block; however, small sample size (10 subjects) may be insufficient to characterize concentration‐response in some cases.
No takes yet. Share an insight, caveat, or question.
Vicente et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: